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If a person who died in the early years
of the twentieth century would come back
today, he would not believe what he saw,
heard, felt, tasted, and smelled. The twenti-
eth century has been a century of so many
discoveries and advances,unprecedented in
any previous era.
Also, the understanding, the prevention,
the diagnosis and treatment of infectious
diseases in pediatrics have made major
leaps forward in the previous century (1).
Eradication of diseases through vaccines
has become possible; proper hygienic mea-
sures have reduced spread of infections
within hospitals tremendously, antibiotics
have allowed us to cure diseases that before
carried a grave prognosis (1). Evidence
based medicine has allowed us to bust
some myths of widely practiced treat-
ments and conclusively proven the effi-
cacy of others. Knowledge and technol-
ogy have grown exponentially and are
continuing to do so in the twenty-first
century (1).
While the exciting discoveries keep
going on, a major challenge ahead of us
lies in the effective processing, application,
and implementation of all new discoveries
of the past and current century. The grand
challenge of this new field of Frontiers in
Pediatrics will focus on two main areas: get-
ting research evidence in practice and new
exciting evidence that could impact clinical
practice.
GETTING RESEARCH INTO PRACTICE
There are many areas where creative
and innovative approaches are very much
needed to give all children in the world a
chance to enjoy optimal health and pro-
tection from infections, based on evidence
created in the last few decades. Below, a few
examples of extremely important areas are
presented.
EFFECTIVE INFECTION CONTROL
Very strong evidence exists, since almost
100 years ago, that proper hand hygiene can
make a huge difference in the incidence of
hospital acquired infections (2, 3). But up
to very recently, studies determining the
compliance of health care workers to hand
hygiene policies showed disturbingly poor
levels of compliance: 20, 40, 80%? Articles
published in the last year still report 40%
pre-intervention and 60% post interven-
tion (4). Why is it not 100%? Simple hand
washing or hand rubbing with disinfec-
tant solution are among the most effective
ways to control hospital infection, but up
to today many places in the world fail to
implement this practice effectively (3).
Many approaches have been tried to
increase hand hygiene compliance and the
success among approaches was variable
at the best, with strategies addressing a
large number of factors (knowledge, aware-
ness, social, behavior, and more) having the
largest effect (5). Very few studies report on
prolonged sustainability of interventions.
We may need to integrate psychological,
behavioral, and management approaches
with clinical medicine and education of
staff to make this very simple but highly
effective method of infection control work
for all children in the world. Novel and cre-
ative approaches improve practice of infec-
tion control within hospitals are definitely
among the priority fields of interest for this
journal.
Also, outside of the healthcare setting,
simple measures to improve the hygiene
of children may have a huge impact.
Overcrowding has since long been known
to be a risk factor for RSV (6). Many of
the epidemics of the respiratory viruses are
now believed to be due to overcrowding in
the houses. In Hong Kong, the higher inci-
dences of RSV were seen in months with
hotter weather, when people preferred to
stay inside rather than to spend the time
outside of the house (7). Contaminated
hands are believed to transfer respiratory
infections much more effective from one
person to another than infected droplets.
It is estimated that through proper hand
washing each person could reduce his
own respiratory infections by more than
60%. RSV transmission is preventable by
increasing hand hygiene, by avoiding sim-
ple things as passive smoking for the high-
risk children (8).
But up to today again, many children are
exposed to these simply avoidable risk fac-
tors and come down with severe infections
that may have been prevented in many
ways. Proper health education is often lack-
ing, even in middle and high-income coun-
tries. In low-income countries, not only
health education is lacking but also the
basic facilities to practice proper hygiene
may be not available to the majority of
families with children. Even though, in our
current times, we know about the DNA
of human beings and bacteria, we know
about protons and bosons and quarks, we
have the most advanced technology avail-
able, too many children still die in today’s
world of infections that were preventable
through simple measures.
VACCINES
Prevention of infection is extremely impor-
tant and many effective vaccines have
been produced since many decades. Major
successes have been achieved through
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immunization. Smallpox is still deemed to
be eradicated (9). Major strides have been
taken toward a polio free world. Measles
has become a rare disease in most mid-
dle and high-income countries. Congenital
rubella has become a perfectly preventable
condition. Tetanus, pertussis diphtheria,
and so many other infectious diseases have
been controlled in major ways through
vaccination (9).
Still there is a large group of people who
have become increasingly vocal, spreading
untrue health beliefs about the damaging
nature of many of the available very effec-
tive and highly safe vaccines. Social media
have given an extra voice to such groups
and if these groups are allowed to spread
their influence they may not only jeopar-
dize the health of their own children but
also compromise the herd immunity,which
is very useful for the small number of chil-
dren with true contra-indications for vacci-
nation. Clinicians can counteract this (10).
Reports on community intervention
programs providing innovative, creative
methods of health education on infec-
tion prevention are a priority area for this
journal.
ANTIBIOTICS
It may be hard today to imagine a world
without antibiotics but <100 years ago, no
antibiotics were around. Antibiotics have
saved numerous lives and they have played
perhaps a pivotal role in the success of
allopathic medicine. Abuse of antibiotic
has led to emerging problems. Of course,
some of the side effects can be particu-
larly nasty and lead to death or life long
sequelae but a main problem with non-
rational use of antibiotics is the emergence
of resistant bacterial strains (11). Again evi-
dence is ample but practice lags behind. Up
to today, antibiotics are abused in many
places. Strict control of antibiotic usage
may reduce resistance dramatically (12).
Avoidance of strong inducers of resistance
such as cephalosporins may have a benefi-
cial effect. Further research is needed. It is
hoped that research into rational antibiotic
usage and control can be reported in this
section of the journal.
VECTOR BORNE DISEASES AND OTHER
MAJOR INFECTIONS
Effective vector control is possible for many
vector borne diseases. However, diseases
as malaria (13) and dengue (14) fever are
still endemic in many parts of the world.
Again bringing the evidence into practice
is lagging behind. HIV and tuberculous,
even though to a high-degree preventable,
claim still many children’s lives every year
worldwide (13).
NEW EVIDENCE
While the mammoth task of getting all
available evidence into practice for all chil-
dren in the world is ongoing, of course
science does not stop. Plenty of new dis-
coveries are made every year. Exciting new
areas of research in pediatric infectious dis-
eases have been explored and many new
areas and discoveries will be made over the
coming decade.
The editors of this journal will welcome
articles reporting contributions to novel
ways of preventing, diagnosing, and treat-
ing infections. The exponentially evolving
fields of genetics, immunology, microbi-
ology, chemistry, and physics combined
with extreme advances in technology to
the nano level (15) and the huge potential
of stem cell therapy (16) seem extremely
promising for the medicine of the future
as a whole. While it is close to impos-
sible to give a comprehensive overview
of all exciting new developments in the
field, a few really important ones will be
highlighted.
The new vaccines for devastating dis-
eases like dengue fever are certainly among
the very relevant developments. Recently, a
commercial dengue vaccine was approved
by the FDA. It delivers only very par-
tial protection (56% reduction in cases)
against dengue fever in the vaccinated
children (17). But more important ques-
tions remain. Antibodies are well known
to play an important role in dengue hem-
orrhagic shock syndrome (18). Will the
acquired partial immunity result in worse
rates of the most feared complication of
dengue once the children become adults
or will it still be protective and benefi-
cial?
Similar questions arise when we talk
about RSV (19), even though recent evi-
dence seems to support that active vacci-
nation against RSV may become available
in the near future depending on the results
of ongoing trials (20). Shall we get bet-
ter vaccines against tuberculosis any time
soon? Is effective safe vaccination against
HIV on the horizon (21) and how will
it be received among extremist religious
groups who imagine they can effectively
prevent the disease exclusively through
moral teachings and policing?
Another worrying development in the
treatment of infectious diseases is the
apparent loss of interest from the indus-
try in developing new antibiotics. In the
last one decade, there has been an ever
decreasing number of new antibiotics com-
ing to the market and being tested (22).
This may be related the lucrative and exor-
bitant profits that can be made through
novel cancer treatments and other emerg-
ing diseases. Multi-drug-resistant (MDR)
organisms (23) are like a sword of Damo-
cles hanging above the future of intensive
care if no effective strategies to prevent
their development and newer antibiotics
become available.
Particularly interesting is that most
antibiotics are used for neonates and chil-
dren off label since economic interest are
not in the favor of children (24). Chemo-
prophylaxis has been studied in a few cases
and short beneficial outcomes have been
reported by hopeful researchers. But long-
term worries about the potential develop-
ment of MDR organisms remain the main
obstacle for implementing these practices
(25). Research in these areas will def-
initely be among the priorities of this
journal.
Pediatric infectious diseases will surely
benefit in many ways from these rapid
advances. These are exciting times. Our
bravest imagination may fall short to figure
out what the future may bring. It is hoped
that this journal will also be a platform
where these developments will be pub-
lished and discussed.
CONCLUSION
It is hoped that this journal can contribute
in a major way to effective implementation
of health interventions that reduce the bur-
den of infection in the community and in
the hospital. Exciting new developments in
pediatric infectious diseases are anticipated
and this will be the place to publish and
read it.
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